A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2(V617F) myeloproliferative neoplasm.
Véronèse
L
L
Tchirkov
A
A
Richard-Pebrel
C
C
Ledoux-Pilon
A
A
Fleury
J
J
Chaleteix
C
C
Goumy
C
C
Gouas
L
L
Berger
M G
MG
Vago
P
P
Bay
J O
JO
Tournilhac
O
O
D000369:Aged, 80 and over; D019943:Amino Acid Substitution / Q000502:physiology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D019008:Drug Resistance, Neoplasm / Q000235:genetics / Q000502:physiology*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D053614:Janus Kinase 2 / Q000235:genetics*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000150:complications / Q000175:diagnosis* / Q000235:genetics; D010649:Phenylalanine / Q000235:genetics; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D013922:Thrombocytosis / Q000139:chemically induced* / Q000235:genetics; D014633:Valine / Q000235:genetics
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D010649:Phenylalanine; D000068877:Imatinib Mesylate; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D014633:Valine